Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments. (Q38569175)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

title

Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

main subject

acute myeloid leukemia

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Elias J Jabbour

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

1 reference

1 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

623-637

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

Therapeutic Advances in Acute Myeloid Leukemia

22 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Acute myeloid leukemia in the elderly: biology and therapeutic strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Results of Therapy for Acute Myeloid Leukemia in First Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

High-dose daunorubicin in older patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Older and new purine nucleoside analogs for patients with acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Biochemical modulation of cytarabine triphosphate by clofarabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Sorafenib treatment of FLT3-ITD( ) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

IDH mutations in glioma and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

IDH1 and IDH2 mutations in pediatric acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

IDH mutations in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Cladribine in the treatment of acute myeloid leukemia: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-015-0285-6

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia

21 January 2018

1 reference

12 December 2020

A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of

1 reference

12 December 2020

The characteristics and outcome of patients with late relapse acute myelogenous leukemia

1 reference

12 December 2020

On the value of intensive remission-induction chemotherapy in elderly patients of 65 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

12 December 2020

Age and acute myeloid leukemia

1 reference

12 December 2020

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

12 December 2020

Expression of normal myeloid-associated antigens by acute leukemia cells

1 reference

12 December 2020

FLAG (fludarabine high-dose cytarabine G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.

1 reference

12 December 2020

Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult

1 reference

12 December 2020

Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission

1 reference

12 December 2020

Prognostic index for adult patients with acute myeloid leukemia in first relapse

1 reference

12 December 2020

Salvage therapy with low-dose cytosine arabinoside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients

1 reference

12 December 2020

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study

1 reference

12 December 2020

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

1 reference

12 December 2020

The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients

1 reference

12 December 2020

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

1 reference

12 December 2020

Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders.

1 reference

12 December 2020

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

1 reference

12 December 2020

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

1 reference

12 December 2020

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

12 December 2020

A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study

1 reference

12 December 2020

Clinical and laboratory studies of 2-chlorodeoxyadenosine /- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults

1 reference

12 December 2020

Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences

1 reference

12 December 2020

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisat

1 reference

12 December 2020

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

12 December 2020

Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate

1 reference

12 December 2020

A randomized study of high-dose cytarabine in induction in acute myeloid leukemia

1 reference

12 December 2020

How I treat older patients with AML

1 reference

12 December 2020

Senior adult oncology clinical practice guidelines in oncology

1 reference

12 December 2020

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

1 reference

12 December 2020

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy

1 reference

12 December 2020

Treatment of older adults with acute myeloid leukemia: state of the art and current perspectives

1 reference

12 December 2020

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

1 reference

12 December 2020

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

12 December 2020

10.1007/S40266-015-0285-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26286093 AND SRC:MED&resulttype=core&format=json

release_ywoupqbkijdrjpzft7vvozupoq

22 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ywoupqbkijdrjpzft7vvozupoq

24 November 2022

mapped directly with Wikidata item

1 reference